eTheRNA
eTheRNA - mRNA Platform
FromeTheRNA
Our mRNA platforms and vast in-house experience help partners quickly optimize, screen and select an mRNA code, develop a candidate, and ensure effective & prime manufacturing of the mRNA from research grade to GMP scale. Our platform’s scale and flexibility is uniquely suited to respond to the needs of development partners across a wide range of therapeutic applications.
Most popular related searches
mrna
T-cell
clinical study
antigen present
antigen presentation
immune stimulating
tumor response
immune stimulation
tumor microenvironment
cancer antigen
Our approach to mRNA chemistry focuses on achieving robust protein expression and is validated across multiple preclinical & clinical studies. Our mRNA platform offering includes a variety of proprietary technologies.
Sequence Optimization
- Sequence optimization algorithms to increase the translation efficiency of the gene of interest by changing compatible codons
- 5’ and 3’ UTRs optimized for expression in human dendritic cells and myocytes
- C- terminal endosomal sorting signal demonstrated to enhance antigen presentation to CD4 and CD8 T cells
- High throughput screening of our in-house library of UTRs to find the best combination for maximized expression in your cell type of interest
Highly pure RNA
- Proprietary mRNA production processes (IVT and purification) optimized for increased purity and, as such, decrease impurity related immunogenicity and toxicity, allowing increased translation efficiency
mRNA based immune-stimulants
- One type of mix is a combination of 3 or 4 mRNAs enhancing T-cell responses to mRNA encoded cancer antigens (TriMix and TetraMix). TriMix has been validated in multiple clinical studies
- We also developed a proprietary mix of mRNAs encoding for signaling proteins that modulate the tumor microenvironment after intratumoral administration which enables the induction of an anti-tumor response